DNA Sequencing Firm Illumina Sees Strong Clinical Market Momentum, Stock Soars

Illumina (NASDAQ:ILMN) shares surged over 21% after the company reported better-than-expected third-quarter results, with adjusted EPS of $1.34 surpassing the $1.17 consensus and revenue of $1.084 billion exceeding estimates, primarily driven by momentum in clinical markets. The DNA sequencing firm also raised its fiscal 2025 adjusted EPS guidance to $4.65-$4.75 and improved its outlook for constant currency revenue decline and adjusted operating margin, indicating a return to growth ex-China. Following the positive report, Evercore ISI maintained an Outperform rating and increased its price target to $142.

Analysis

Illumina (ILMN) reported robust third-quarter results, with adjusted earnings of $1.34 per share significantly exceeding the $1.17 consensus and revenue reaching $1.084 billion, surpassing estimates of $1.065 billion. This strong performance, primarily driven by high single-digit growth in sequencing consumables revenue within the clinical markets, led to a substantial 21.45% surge in ILMN shares to $120.24.

CEO Jacob Thaysen highlighted a return to growth ex-China and successful execution on strategic pillars, underscoring the company's operational strength. The placement of over 55 NovaSeq X instruments in the quarter also met the company's goal, indicating solid adoption of its advanced sequencing technology.

The company raised its fiscal 2025 adjusted EPS guidance to $4.65-$4.75, above the $4.50 consensus, and improved its constant currency revenue decline forecast. This upward revision, combined with Evercore ISI maintaining an Outperform rating and increasing its price target to $142, reflects heightened analyst confidence in Illumina's future trajectory.

Key Decisions for Investors

• Investors should evaluate the significantly raised fiscal 2025 guidance and strong Q3 performance, particularly the return to growth ex-China, as potential catalysts for continued positive momentum.
• Monitor the company's execution on strategic pillars and NovaSeq X instrument placements, as these are key indicators for sustained long-term growth in clinical markets.
• Consider the updated Evercore ISI price target of $142, which reflects increased analyst confidence following the earnings beat and improved outlook, when assessing current valuation.